scholarly journals PO-375 Analysis of miRNA expression in non-small cell lung cancer

2018 ◽  
Author(s):  
V Petkova ◽  
A Mitkova ◽  
D Kachakova ◽  
G Stancheva ◽  
S Giragosyan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Mirna Expression ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals A Novel Composite Biomarker Panel For Detection Of Early Stage Non-small Cell Lung Cancer

2021 ◽  
Vol 44 (1) ◽  
pp. E15-24
Author(s):  
Eric L.R. Bédard ◽  
Aswin G. Abraham ◽  
Anil A. Joy ◽  
Sunita Ghosh ◽  
Xiaoyu Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Mirna Expression ◽  
Roc Analysis ◽  
Early Stage ◽  
Small Cell ◽  
Proton Nuclear Magnetic Resonance ◽  
Small Cell Lung ◽  
Urine Metabolites

Purpose: To investigate a novel composite methodology of using targeted serum microRNAs (micro ribonucleic acid; miRNA) and urine metabolites for the accurate detection of early stage non-small cell lung cancer (NSCLC). Methods: Consecutively consenting NSCLC patients and matched control subjects were recruited to provide samples of serum for miRNA and/or urine for metabolite analyses. Serum miRNA levels were measured using quantitative real-time reverse-transcription with exogenous control, and the comparative delta cycle threshold (&#9651CT) method was used to calculate relative miRNA expression of two targeted miRNAs (miR-21 and miR-223). The concentrations of six targeted urinary metabolites in patients and healthy controls were measured using proton nuclear magnetic resonance (1H NMR) spectroscopy. A composite methodology of using the 35 accruals with both serum and urine biomarkers was then established with binary logistic regression, receiver operating characteristic (ROC) models with or without artificial intelligence (AI). Results: The ROC analysis of miRNA expression yielded a sensitivity of 96.4% and a specificity of 88.2% for the detection of early stage NSCLC, with area under the curve (AUC) = 0.91 (CI 95%: 0.80-1.0). Relative urinary concentrations of 4-methoxyphenylacetic acid (4MPLA) were significantly different between NSCLC and healthy control (p=0.008). The ROC analysis of 4MPLA yielded a sensitivity of 82.1% and a specificity of 88.2%, with AUC = 0.85. The composite process combining miRNA and metabolite expression demonstrated a sensitivity and specificity of nearly 100% and AUC=1. Conclusions: A highly specific, sensitive and non-invasive detection method for NSCLC was developed. Pending validation, this can potentially improve the early detection and, hence, the treatment and survival outcomes of patients.

scholarly journals Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer

Lung Cancer ◽  
2010 ◽  
Vol 67 (2) ◽  
pp. 170-176 ◽  
Author(s):  
Ying Xie ◽  
Nevins W. Todd ◽  
Zhenqiu Liu ◽  
Min Zhan ◽  
HongBin Fang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Mirna Expression ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Long-Term Cigarette Smoke Exposure and Changes in MiRNA Expression and Proteome in Non-Small-Cell Lung Cancer

2017 ◽  
Vol 21 (7) ◽  
pp. 390-403 ◽  
Author(s):  
Jayshree Advani ◽  
Yashwanth Subbannayya ◽  
Krishna Patel ◽  
Aafaque Ahmad Khan ◽  
Arun H. Patil ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cigarette Smoke ◽  
Cell Lung Cancer ◽  
Mirna Expression ◽  
Small Cell ◽  
Smoke Exposure ◽  
Cigarette Smoke Exposure ◽  
Small Cell Lung

scholarly journals Sensitivity of Plasma Micrornas as a Probable Non-Small Cell Lung Cancer Biomarker and Its Significance

2021 ◽  
Vol 15 (7) ◽  
pp. 1877-1881
Author(s):  
Qazi Talal Ali ◽  
Muhammad Javaid Iqbal ◽  
Ayesha Masood ◽  
Aamir Hussain ◽  
Muhammad Usman
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Mirna Expression ◽  
Tumor Tissue ◽  
Lung Tumor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Less Invasive ◽  
Potential Biomarker

Non-small cell lung cancer (NSCLC) is the chief origin of death due to cancer. The development of a less invasive diagnostic technique for NSCLC, especially at the beginning, can improve outcomes. By means of microarray platforms, we formerly diagnosed 12 microRNAs (miRNAs) abnormally expressed in primary cancer cells associated with early NSCLC. Objective: In this study, we will extend previous studies to determine if miRNAs may be beneficial as a NSCLC potential plasma biomarker. Methods: We primarily confirmed miRNA expression from PCR of 32 stage one NSCLC patients with lung tumor and plasma specimens were assessed, then assessed the investigative value of plasma miRNAs in 61 patients of NSCLC and 30 normal subjects. It was confirmed that the alteration of MiRNA expression influences the regeneration of neoplastic tumors. MiRNAs were steady and reliable in plasma measurements. The cohort consisted of 21 men and 11 women. Their age ranges from 47 to 80 years. AC tumors were classified in 17 and SCC in 15 patients. Smoking packets use in these patients were 39 ± 28. In addition, IV blood were taken from healthy subjects with matched data distribution to studied group as age, race, sex and smoking, and aided as a control to evaluate fluctuations in plasma in cancer patients. Results: Five out of 12 miRNAs showed a significant change of level in plasma and the corresponding tumor tissue (all r40850, all P< 0.05). Four genes (miRNA-126, 21, 486-5 and 210p) set the best logistic regression pattern, with 87% sensitivity and 97% of specificity of at the time of NSCLC in differentiating from healthy patients. Moreover, the miRNA genes generated a sensitivity of 79.41% and 92.59% of specificity in patients diagnosed with SCC and AC. Moreover, genes have specificity of 96.67% in the analysis of lung adenocarcinoma and squamous cell carcinoma. (P less than 0.05). A change in square miRNA expression may offer potential NSCLC blood-derived biomarker. Conclusion: Finally, we show that miRNA expression identified from surgical tumor tissue can be easily and correctly determined in plasma. Though, prominently, a plasma miRNA recognition panel would be cast-off as a less invasive analytic method for NSCLC, including long-term adenocarcinoma. However, the presence of an independent potential biomarker requires further verification. Keywords: Lung cancer; Diagnosis; Plasma; Microrna; Qrt-PCR

scholarly journals Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non–Small Cell Lung Cancer by Quantitative Real-Time RT-PCR

2008 ◽  
Vol 54 (10) ◽  
pp. 1696-1704 ◽  
Author(s):  
Athina Markou ◽  
Emily G Tsaroucha ◽  
Loukas Kaklamanis ◽  
Marianthi Fotinou ◽  
Vassilis Georgoulias ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Real Time ◽  
Cell Lung Cancer ◽  
Mirna Expression ◽  
Prognostic Value ◽  
Small Cell ◽  
Rt Pcr ◽  
Small Cell Lung ◽  
Mature Microrna

Abstract Background: microRNA (miRNA) expression profiles are being intensively investigated for their involvement in carcinogenesis. We evaluated the prognostic value of mature microRNA-21 (miR-21) and mature microRNA-205 (miR-205) overexpression in non–small cell lung cancer (NSCLC). Patients and methods: We studied 48 pairs of NSCLC fresh frozen tissue specimens collected at time of surgery and before chemotherapy. Highly specific amplification and quantification of mature miR-21 and mature miR-205 was achieved using looped real time RT-PCR. Results: miRNA expression, determined by real time RT-PCR, was defined by ΔΔCt measurements. We detected overexpression of mature miR-21 in 25 (52.0%) of the 48 NSCLC paired specimens and overexpression of miR-205 in 31 (64.6%). Overexpression was assessed after comparison of miRNA expression in NSCLC tissues and in their corresponding noncancerous tissues with respect to U6 expression. During the follow-up period, 29 of 48 (60.4%) patients relapsed, and 23 of 48 died (47.9%). Mature miR-21 was upregulated in 16 of 29 (55.2%) patients who relapsed and 15 of 23 (65.2%) patients who died. Mature miR-205 was overexpressed in 19 of 29 patients who relapsed (65.5%) and 15 of 23 patients who died (65.2%). Mature miR-21 overexpression correlated with overall survival (OS) of the patients (P = 0.027), whereas overexpression of mature miR-205 did not. Conclusions: Our results suggest that overexpression of mature miR-21 is an independent negative prognostic factor for OS in NSCLC patients.

scholarly journals Sensitivity of Plasma Micro RNAs as a Probable Non-Small Cell Lung Cancer Biomarker and its Significance

2021 ◽  
pp. 161-169
Author(s):  
Zarmeen Sultan ◽  
Zuby Tufail ◽  
Muazzma Siddiqa
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Mirna Expression ◽  
Tumor Tissue ◽  
Small Cell ◽  
Small Cell Lung ◽  
Less Invasive ◽  
Potential Biomarker ◽  
Micro Rnas

Non-small cell lung cancer (NSCLC) is the chief origin of death due to cancer. The development of a less invasive diagnostic technique for NSCLC, especially at the beginning, can improve outcomes. By means of microarray platforms, we formerly diagnosed 12 microRNAs (miRNAs) abnormally expressed in primary cancer cells associated with early NSCLC. Objective: In this study, we will extend previous studies to determine if miRNAs may be beneficial as a NSCLC potential plasma biomarker. Methods: We primarily confirmed miRNA expression from PCR of 32 stage one NSCLC patients with lung tumor and plasma specimens were assessed, then assessed the investigative value of plasma miRNAs in 61 patients of NSCLC and 30 normal subjects. It was confirmed that the alteration of MiRNA expression influences the regeneration of neoplastic tumors. MiRNAs were steady and reliable in plasma measurements. The cohort consisted of 21 men and 11 women. Their age ranges from 47 to 80 years. AC tumors were classified in 17 and SCC in 15 patients. smoking packets use in these patients were 39 ± 28. In addition, IV blood were taken from healthy subjects with matched data distribution to studied group as age, race, sex and smoking, and aided as a control to evaluate fluctuations in plasma in cancer patients. Results: Five out of 12 miRNAs showed a significant change of level in plasma and the corresponding tumor tissue (all r40850, all P< 0.05). Four genes (miRNA-126, 21, 486-5 and 210p) set the best logistic regression pattern, with 87% sensitivity and 97% of specificity of at the time of NSCLC in differentiating from healthy patients. Moreover, the miRNA genes generated a sensitivity of 79.41% and 92.59% of specificity in patients diagnosed with SCC and AC. Moreover, genes have specificity of 96.67% in the analysis of lung adenocarcinoma and squamous cell carcinoma. (P less than 0.05). A change in square miRNA expression may offer potential NSCLC blood-derived biomarker. Conclusion: Finally, we show that miRNA expression identified from surgical tumor tissue can be easily and correctly determined in plasma. Though, prominently, a plasma miRNA recognition panel would be cast-off as a less invasive analytic method for NSCLC, including long-term adenocarcinoma. However, the presence of an independent potential biomarker requires further verification.

Sign in / Sign up

Export Citation Format

Share Document